
Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for …